Sign in Subscribe
Cancer

Gene Therapy Shows Promise in Treating Oral Cancer

Strategic Insights

— 1 min read

Researchers at Niigata, Japan's The Nippon Dental University have made significant breakthroughs in the field of cancer gene therapy, specifically targeting oral cancer. Their experimental study, published in Odontology, aimed to investigate the effectiveness of an antiangiogenic gene therapy that inhibits the growth of new blood vessels that feed tumors. The study involved administering a soluble form of VEGF receptor-expressing gene to nude mice transplanted with oral cancer cell lines. The results showed a significant antiproliferative effect, with tumors being enucleated and examined histopathologically and immunohistologically.

Key Takeaways:

  • The study aimed to investigate the effectiveness of antiangiogenic gene therapy targeting VEGF in oral cancer, with a focus on inhibiting angiogenesis.
  • The researchers administered a soluble form of VEGF receptor-expressing gene to nude mice transplanted with oral cancer cell lines, resulting in significant antiproliferative effects.
  • Tumor volumes were measured over time, and tumors were examined histopathologically and immunohistologically to assess the effectiveness of the therapy.
  • The results suggest that gene therapy via soluble VEGF receptor-expressing gene would be an effective oral cancer therapy and could benefit future clinical applications.
  • The study highlights the potential of gene therapy as a treatment option for oral cancer, with VEGF being a key target for antiangiogenic therapy.
  • Y. Okada, The Nippon Dental University, Dept. of Pathology, School of Life Dentistry at Niigata

Statistics:

  • 52-9: The page numbers on which the study was published in Odontology.
  • 1-8 Hamaura-cho, Chuo-ku, Niigata, 951-8580: The address of The Nippon Dental University.
  • 143: The number of cell lines (SAS, HSC-3, and Ca9-22) used in the study.
  • 28 days: The duration after AdVEGF-ExR administration during which tumors were enucleated and examined histopathologically and immunohistologically.
  • p < 0.05: The significance level at which the antiproliferative effects were observed compared to controls.

Sources:

  • Okada Y. et al. Experimental study of antiangiogenic gene therapy targeting VEGF in oral cancer. Odontology, 2010;98(1):52-9.
  • NewsRx.com. Cancer Gene Therapy Week. 2010.

Read more